Onyx Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

Onyx Pharmaceuticals (ONXX)

Q2 2012 Earnings Call

August 01, 2012 5:00 pm ET

Executives

Amy Figueroa

N. Anthony Coles - Chief Executive Officer, President and Director

Helen Torley - Chief Commercial officer and Executive Vice President

Matthew K. Fust - Chief Financial Officer, Principal Accounting Officer and Executive Vice President

Barbara Klencke

Analysts

Michael G. King - Rodman & Renshaw, LLC, Research Division

Cory William Kasimov - JP Morgan Chase & Co, Research Division

Terence C. Flynn - Goldman Sachs Group Inc., Research Division

Rachel L. McMinn - BofA Merrill Lynch, Research Division

Howard Liang - Leerink Swann LLC, Research Division

Biren Amin - Jefferies & Company, Inc., Research Division

Matthew R. Wooten - Robert W. Baird & Co. Incorporated, Research Division

Navdeep Singh - Deutsche Bank AG, Research Division

Geoffrey C. Porges - Sanford C. Bernstein & Co., LLC., Research Division

Ling Wang - Summer Street Research Partners

Echo Yinghui He - Maxim Group LLC, Research Division

Ryan Martins - Lazard Capital Markets LLC, Research Division

Nicholas Bishop - Cowen and Company, LLC, Research Division

Ying Huang - Barclays Capital, Research Division

Marshall Urist - Morgan Stanley, Research Division

Jim Birchenough - BMO Capital Markets U.S.

Presentation

Operator

Welcome to the Onyx Pharmaceuticals Conference Call. My name is Trish, and I will be your operator for today's call. [Operator Instructions] Please note that this conference is being recorded.

I would now like to turn the call over to Onyx Pharmaceuticals.

Amy Figueroa

Thanks, Trish. Good afternoon. I'm Amy Figueroa, Senior Director of Investor Relations at Onyx Pharmaceuticals. Thank you for participating on our second quarter 2012 financial results conference call.

If you liked this article you might like

Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet; Global Blood Weighs on Bluebird

The Street Can't Help but Love Amgen

Biotech Stock Bubble Talk Deflated By Cost-Conscious Buyers

Trade-Ideas: Onyx Pharmaceuticals (ONXX) Is Today's "Water-Logged And Getting Wetter" Stock

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan